Skip to main content

Table 1 Baseline patient characteristics

From: Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma

Total patients, n

50

Median age, years (range)

56 (21–80)

Sex (Females: Males)

22:28

Diagnosis, n (%)

 Hodgkin lymphoma (HL)

14 (28%)

 Follicular lymphoma (FL)

13 (26%)

 Diffuse large B-cell lymphoma (DLBCL)

7 (14%)

 Mantle Cell lymphoma (MCL)

4 (8%)

 Low-grade B-cell lymphoma unclassifiable

4 (8%)

 Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

2 (4%)

 Burkitt lymphoma

1 (2%)

 Post-transplant lymphoproliferative disorder (PTLD)

2 (4%)

 Othersa

3 (6%)

Ann Arbor Stage

 Stage I

11 (22%)

 Stage II

6 (12%)

 Stage III

8 (16%)

 Stage IV

24 (48%)

 Otherb

1 (2%)

  1. aOthers = One case each of monoclonal B-cell lymphocytosis (MBL) with a chronic lymphocytic leukemia (CLL) immunophenotype, small lymphocytic lymphoma, orbital mucosa-associated lymphoid tissue (MALT)
  2. bA single case of suspected B-cell lymphoma which was subsequently confirmed as MBL with CLL immunophenotype